Clinical Trials » Stargardt Disease
Subretinal Implant: Retina AG
Description: Retina AG, a German developer of subretinal implants, is conducting international clinical evaluations of its subretinal implant for providing limited vision to people with advanced retinal degenerative diseases such as retinitis pigmentosa. The company reported that a majority of 11 subjects in the study were able to “pick out” bright objects. The chip, placed behind the macula, works by converting light entering the eye into electrical impulses which are then sent to the optic nerve. The device has been in human evaluations since 2005. Current clinical evaluation sites are located in: Germany, United Kingdom, Hungary, Italy, and the United States (Wills Eye Institute, Philadelphia).
Trial Status: Ongoing; recruiting participants.
Retina AG’s clinical trial listing on ClinicalTrials.gov